Abstracts tagged "animal models and treatment"

Abstract Number: 1326 • 2017 ACR/ARHP Annual Meeting
Alpha-Glucosidase Inhibitors Alter Gut Microbiota and Ameliorate Collagen-Induced Arthritis
Lingshu Zhang^1,2, Pingfang Song², Xiaowei Zhang², Christina Metea², Matthew Schleisman², Lisa Karstens², Eric Leung², Jun Zhang³, Qiang Xu^2,4, Yi Liu⁵, Mark Asquith² and Cong-Qiu Chu^6,7, ¹Department of Rheumatology, West China Hospital, Sichuan University, Chengdu, China, ²Oregon Health & Science University, Portland, OR, ³MD Anderson Cancer Center, Houston, TX, ⁴Guangzhou University of Chinese Medicine, Guangzhou, China, ⁵Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China, ⁶Rheumatology, Oregon Health & Science University, Portland, OR, ⁷Rheumatology, VA Portland Health Care System, Portland, OR
Background/Purpose: Acarbose, an alpha-glucosidase inhibitor anti-diabetic drug exhibited anti-arthritic effects. The mechanism that acarbose exerts its anti-arthritic effects is not fully understood. Since > 90%…
Abstract Number: 2234 • 2013 ACR/ARHP Annual Meeting
Targeting Therapy Of Citrullinated Antigen-Specific B Cells Ameliorates Collagen-Induced Arthritis
Kazuya Michishita¹, Kimito Kawahata¹, Takeyuki Kanzaki², Lisa Akahira¹, Toshiki Eri¹ and Kazuhiko Yamamoto³, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Internal Medicine, Yamanashi Prefectural Central Hospital, Yamanashi, Japan, ³Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: The clinical benefit of B-cell depletion therapy in rheumatoid arthritis(RA) is a well-known fact, but problems such as relapse of tuberculosis and reactivation of…
Abstract Number: 2083 • 2012 ACR/ARHP Annual Meeting
New Treatment Approach of Rheumatoid Arthritis Based On Inhibition of Cyclin Dependent Kinase-9
Annelie Hellvard¹, Lutz Zeitlmann², Ulrich Heiser³, André Niestroj³, Hans-Ulrich Demuth³, Jan Potempa⁴ and Piotr Mydel¹, ¹Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Bergen, Norway, ²Ingenium Pharmaceuticals GmbH, Martinsried, Germany, ³Probiodrug AG, Halle/Saale, Germany, ⁴Microbiology Department, Jagiellonian University, Krakow, Poland
Background/Purpose: Cyclin dependent kinase-9 (cdk-9) is transcription regulator of the carboxyterminal domain of RNA polymerase II. The usage of pan-cdk inhibitors such as flavopiridol has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].